Company: ZVRA
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001434647-25-000011
Chunk: 52

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 52
---
,778)$(43)$61,864 Net loss— — — (16,622)— (16,622)Stock-based compensation expense— 2,190 — — — 2,190 Issuance of common stock in exchange for consulting services— 56 — — — 56 Issuance of common stock for options exercised— 1,146 — — — 1,146 Other comprehensive income— — — — 184 184 Balance as of March 31, 2024$4 $476,056 $(10,983)$(416,400)$141 $48,818 Net loss— — — (19,925)— (19,925)Stock-based compensation expense— 2,688 — — — 2,688 Issuance of common stock in exchange for consulting services— 193 — — — 193 Issuance of common stock as part of the Employee Stock Purchase Plan— 424 — — — 424 Other comprehensive income— — — — 280 280 Balance as of June 30, 2024$4 $479,361 $(10,983)$(436,325)$421 $32,478 Net loss— — — (33,225)— (33,225)Stock-based compensation expense— 6,229 — — — 6,229 Issuance of common stock in public offering1 64,516 — — — 64,517 Issuance of common stock in exchange for consulting services— 150 — — — 150 Issuance of common stock for options exercised — 157 — — — 157 Other comprehensive loss— — — — (536)(536)Balance as of September 30, 2024$5 $550,413 $(10,983)$(469,550)$(115)$69,770 

See accompanying notes to unaudited condensed consolidated financial statements.

8

ZEVRA THERAPEUTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Nine months ended September 30,20252024Cash flows from operating activities:Net income (loss